Recommendations for assessing Patient‐Reported Outcomes and Health‐Related quality of life in clinical trials on allergy: a GA2LEN taskforce position paper
- 3 February 2010
- Vol. 65 (3), 290-295
- https://doi.org/10.1111/j.1398-9995.2009.02263.x
Abstract
To cite this article: Baiardini I, Bousquet PJ, Brzoza Z, Canonica GW, Compalati E, Fiocchi A, Fokkens W, van Wijk RG, La Grutta S, Lombardi C, Maurer M, Pinto AM, Ridolo E, Senna GE, Terreehorst I, Todo Bom A, Bousquet J, Zuberbier T, Braido F. Recommendations for assessing Patient‐Reported Outcomes and Health‐Related quality of life in clinical trials on allergy: a GA2LEN taskforce position paper. Allergy 2010; 65: 290–295. Abstract The aim of this Global Allergy and Asthma European Network (GA2LEN) consensus report is to provide recommendations for patient‐reported outcomes (PROs) evaluation in clinical trials for allergic diseases, which constitute a global health problem in terms of physical, psychological economic and social impact. During the last 40 years, PROs have gained large consideration and use in the scientific community, to gain a better understanding of patients’ subjective assessment with respect to elements concerning their health condition. They include all health‐related reports coming from the patient, without involvement or interpretation by physician or others. PROs assessment should be performed by validated tools (disease‐specific tools when available or generic ones) selected taking into account the aim of the study, the expected intervention effects and the determinant and confounding factors or patient‐related factors which could influence PROs. Moreover, each tool should be used exclusively in the patient population following the authors’ indications without modification and performing a cross‐cultural validation if the tool must be used in a language that differs from the original. The result analysis also suggests that the relevance of PROs results in any interventional study should include a pre–post assessment providing information concerning statistical differences within or among groups, rates of response for the PROs and a minimal important difference for the population. The report underlines the importance of further investigation on some topics, such as the quality assessment of existing PROs tools, the definition of inclusion and exclusion criteria and a more extensive evaluation of the correlation between PROs, besides health‐related quality of life, and clinical data.This publication has 40 references indexed in Scilit:
- The use of patient-reported outcomes instruments in registered clinical trials: Evidence from ClinicalTrials.govContemporary Clinical Trials, 2009
- Chronic urticaria: a patient survey on quality‐of‐life, treatment usage and doctor–patient relationAllergy, 2009
- The impact of GINA suggested drugs for the treatment of asthma on Health‐Related Quality of Life: a GA2LEN reviewAllergy, 2008
- ARIA‐suggested drugs for allergic rhinitis: what impact on quality of life? A GA2LEN ReviewAllergy, 2008
- Undertreatment of rhinitis symptoms in Europe: findings from a cross‐sectional questionnaire surveyAllergy, 2007
- AKL1, a botanical mixture for the treatment of asthma: a randomised, double-blind, placebo-controlled, cross-over studyBMC Pulmonary Medicine, 2007
- Methods to Explain the Clinical Significance of Health Status MeasuresMayo Clinic Proceedings, 2002
- Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status QuestionnaireJournal of Allergy and Clinical Immunology, 1994
- Cross-cultural adaptation of health measuresHealth Policy, 1991
- Bias in analytic researchJournal of Chronic Diseases, 1979